Home > Cardiology > Inclisiran Lowers Cholesterol Across All BMI groups

Inclisiran Lowers Cholesterol Across All BMI groups

Expert
Dr Lawrence A. Leiter, Clinical Nutrition and Risk Factor Modification Centre

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AHA 2021
A post-hoc analysis of the data from the ORION-9, ORION-10, and ORION-11 trials, presented during the 2021 American Heart Association (AHA) Scientific Sessions, showed that inclisiran treatment every 6 months resulted in effective and sustained reduction of approximately 50% in low-density lipoprotein cholesterol (LDL-C) across all body weights when used in addition to other lipid-lowering therapies [1]. Dr Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto, presented this analysis. Medicom interviewed him to ask why it is important to find lipid-lowering treatments for patients across all ranges of body mass indexes (BMI).


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on